Petruzziello Arnolfo, Marigliano Samantha, Loquercio Giovanna, Cozzolino Anna, Cacciapuoti Carmela
Arnolfo Petruzziello, Samantha Marigliano, Giovanna Loquercio, Anna Cozzolino, Carmela Cacciapuoti, Laboratory of Virology and Molecular Biology "V.Tridente", IRCCS Italia, Fondazione " G. Pascale", 80131 Naples, Italy.
World J Gastroenterol. 2016 Sep 14;22(34):7824-40. doi: 10.3748/wjg.v22.i34.7824.
To review Hepatitis C virus (HCV) prevalence and genotypes distribution worldwide.
We conducted a systematic study which represents one of the most comprehensive effort to quantify global HCV epidemiology, using the best available published data between 2000 and 2015 from 138 countries (about 90% of the global population), grouped in 20 geographical areas (with the exclusion of Oceania), as defined by the Global Burden of Diseases project (GBD). Countries for which we were unable to obtain HCV genotype prevalence data were excluded from calculations of regional proportions, although their populations were included in the total population size of each region when generating regional genotype prevalence estimates.
Total global HCV prevalence is estimated at 2.5% (177.5 million of HCV infected adults), ranging from 2.9% in Africa and 1.3% in Americas, with a global viraemic rate of 67% (118.9 million of HCV RNA positive cases), varying from 64.4% in Asia to 74.8% in Australasia. HCV genotype 1 is the most prevalent worldwide (49.1%), followed by genotype 3 (17.9%), 4 (16.8%) and 2 (11.0%). Genotypes 5 and 6 are responsible for the remaining < 5%. While genotypes 1 and 3 are common worldwide, the largest proportion of genotypes 4 and 5 is in lower-income countries. Although HCV genotypes 1 and 3 infections are the most prevalent globally (67.0% if considered together), other genotypes are found more commonly in lower-income countries where still account for a significant proportion of HCV cases.
A more precise knowledge of HCV genotype distribution will be helpful to best inform national healthcare models to improve access to new treatments.
回顾全球丙型肝炎病毒(HCV)的流行情况及基因型分布。
我们进行了一项系统研究,这是量化全球HCV流行病学的最全面努力之一,使用了2000年至2015年期间来自138个国家(约占全球人口的90%)的最佳可用已发表数据,这些国家按全球疾病负担项目(GBD)定义的20个地理区域分组(不包括大洋洲)。对于我们无法获得HCV基因型流行率数据的国家,在计算区域比例时将其排除,尽管在生成区域基因型流行率估计值时,其人口被纳入每个区域的总人口规模。
全球HCV总流行率估计为2.5%(1.775亿例HCV感染成年人),非洲为2.9%,美洲为1.3%,全球病毒血症率为67%(1.189亿例HCV RNA阳性病例),亚洲为64.4%,大洋洲为74.8%。HCV基因型1在全球最为普遍(49.1%),其次是基因型3(17.9%)、4(16.8%)和2(11.0%)。基因型5和6占其余不到5%。虽然基因型1和3在全球都很常见,但基因型4和5的最大比例存在于低收入国家。尽管HCV基因型1和3感染在全球最为普遍(若合并考虑则为67.0%),但其他基因型在低收入国家更为常见,在这些国家它们仍占HCV病例的很大比例。
更精确地了解HCV基因型分布将有助于为国家医疗保健模式提供最佳信息,以改善获得新治疗方法的机会。